Biogen (BIIB) Stock
Key stats
- Market cap
- $37.46B
- Price / Earnings ratio
- 107.7x
- EPS (TTM)
- $2.36
- Volume
- Loading
- 52-week high
- $261.00
- 52-week low
- $154.20
- EPS vs analyst estimate
- +23.7%Q3 FY25 · $4.81 vs $3.89
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with BIIB
Recent news
Biogen Q3 Earnings Call Highlights
Biogen Q3 Earnings Call Highlights
BIIB
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
BIIB
Big Day for Econ Data, Hyperscaler Earnings
Big Day for Econ Data, Hyperscaler Earnings
BIIB
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
BIIBNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.93
- MACD 12/26/9
- 6.13
- EMA 9 of MACD
- 6.52
- MACD histogram
- -0.39
- SMA 50
- $232.21
- Price above SMA 50
- EMA 50
- $235.10
- Price above EMA 50
- SMA 200
- $204.39
- Price above SMA 200
- EMA 200
- $207.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.68 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Biogen Q3 Earnings Call Highlights
Biogen Q3 Earnings Call Highlights
BIIBBIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
BIIBBig Day for Econ Data, Hyperscaler Earnings
Big Day for Econ Data, Hyperscaler Earnings
BIIBBiogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
BIIB
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
BIIB
Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report
Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report
BIIB
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
BIIB
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
BIIB
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
BIIB
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BIIBNews tone: automated (AI) classification of the article's content, not a price prediction.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Viehbacher | President, CEO & Director | 1961 |
| Ms. Robin C. Kramer | Executive VP & CFO | 1966 |
| Ms. Nicole Murphy | Executive VP and Head of Pharmaceutical Operations & Technology | 1973 |
| Dr. Priya Singhal M.D., M.P.H. | Executive VP & Head of Development | 1968 |
| Mr. Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 1974 |
| Mr. Guy Hadari | Chief Information Officer | — |
| Mr. Tim Power M.B.A., Ph.D. | Head of Investor Relations | — |
| Mr. Michael John Parini J.D. | Chief Legal Officer | 1974 |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | — |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | 1977 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 59.93
- MACD 12/26/9
- 6.13
- EMA 9 of MACD
- 6.52
- MACD histogram
- -0.39
- SMA 50
- $232.21
- Price above SMA 50
- EMA 50
- $235.10
- Price above EMA 50
- SMA 200
- $204.39
- Price above SMA 200
- EMA 200
- $207.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $175.00
- Average
- $267.83
- High
- $310.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.3 | +4.5 | ||||||||||
| 2022 | -7.4 | -8.0 | +0.1 | -1.5 | -3.5 | +2.0 | +2.1 | -6.6 | +33.6 | +7.2 | +9.0 | -8.3 |
| 2023 | +6.7 | -7.5 | +2.1 | +9.7 | -4.7 | -5.8 | -5.3 | -0.7 | -3.8 | -6.1 | -2.3 | +10.3 |
| 2024 | -7.9 | -12.4 | -2.4 | -0.0 | +4.1 | +0.9 | -8.0 | -2.8 | -5.4 | -8.8 | -7.6 | -6.9 |
| 2025 | -4.0 | -1.3 | -3.4 | -8.3 | +7.3 | -4.2 | -1.6 | +0.2 | +0.3 | +0.0 | +20.2 | -1.0 |
| 2026 | +1.2 | +7.1 | -2.5 | +3.0 | +4.8 | +12.4 | -3.2 | +7.3 | +4.6 | +13.8 | +1.8 |
